Table 1.

Demographic and comorbidity data of breast cancer patients classified by tamoxifen use status.

	Breast cancer						P value
	All n = 81,371		Without tamoxifen use n = 30,929		With tamoxifen use n = 50,442
Variable	n	%	n	%	n	%
Age, years							<0.001
20–44	21,556	26.5	7,075	22.9	14,481	28.7
45–64	47,179	58.0	18,588	60.1	28,591	56.7
≥65	12,636	15.5	5,266	17.0	7,370	14.6
Means (SD)a	52.6	11.7	53.7	11.9	51.9	11.6	<0.001
Comorbidity
CAD	10,426	12.8	4,069	13.2	6,357	12.6	0.02
COPD	6,308	7.75	2,452	7.93	3,856	7.64	0.14
Stroke	1,901	2.34	891	2.88	1,010	2.00	<0.001
Alcohol-related illness	1,220	1.50	459	1.48	761	1.51	0.78
Hypertension	23,924	29.4	9,506	30.7	14,418	28.6	<0.001
Diabetes	8,092	9.94	3,272	10.6	4,820	9.56	<0.001
Drug
Steroids	47,754	58.7	18,009	58.2	29,745	59.0	0.04
Statins	10,349	12.7	4,375	14.2	5,974	11.8	<0.001
Thiazide diuretics	19,215	23.6	7,785	25.2	11,430	22.7	<0.001
Treatment I = local therapy
Breast surgery	70,120	86.2	25,122	81.2	44,998	89.2	<0.001
Radiotherapy	38,873	47.8	13,229	42.8	25,644	50.8	<0.001
Treatment II = other (neo) adjuvant systemic treatment
Other systemic treatment with aromatase inhibitor alone	3,886	4.78	1,141	3.69	2,745	5.44	<0.001
Other systemic treatment with chemotherapy alone	40,720	50.0	18,341	59.3	22,379	44.4	<0.001
Other systemic treatment with AI + CT	16,493	20.3	3,611	11.7	12,882	25.5	<0.001

Chi-square test; ^aStudent t test.

AI, aromatase inhibitor; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease, SD, standard deviation.